Save time and get answers to complex questions with AI chat
Zemdri nce gain exclusivity 2028 patent 2031?Xiaflex market launch year?Excipients list used in dexamethasone creams?What excipients are combined with ruxolitinib in apotex's medication?When is the expected fda decision date for apotex's ruxolitinib resubmission?
See the DrugPatentWatch profile for klisyri
Klisyri (tirbanibulin) is indicated for the treatment of actinic keratosis on the face or scalp [1]. That means it can be used for lesions located on the face (and also on the scalp) [1].
The approved label indication is specifically for actinic keratosis on the face or scalp, not other body areas [1]. If your lesions are outside the face/scalp locations, your clinician may need to consider an alternative treatment.
Because Klisyri’s indication is limited to the face or scalp, it would generally not be the labeled choice for actinic keratosis on areas like the hands or forearms [1]. Treatment for those locations is typically different and depends on the site and extent of disease.
DrugPatentWatch lists the indication for Klisyri as actinic keratosis on the face or scalp [1]. Sources [1] https://www.drugpatentwatch.com/meds/klisyri-tirbanibulin
Other Questions About Klisyri :